Your browser doesn't support javascript.
loading
High-Grade, Stage 2 Mast Cell Tumors: Outcome in Dogs With Local and Systemic Therapy.
Burge, Rhonda; Woolard, Kevin D; Willcox, Jennifer L; Rebhun, Robert B; Burton, Jenna H; Al-Nadaf, Sami; Skorupski, Katherine A.
Afiliação
  • Burge R; From the Department of Veterinary Clinical Sciences (R.B.), College of Veterinary Medicine, The Ohio State University, Columbus, Ohio.
  • Woolard KD; Department of Pathology, Microbiology, and Immunology (K.D.W.), School of Veterinary Medicine, University of California, Davis, California.
  • Willcox JL; Department of Surgical and Radiological Sciences (J.L.W., R.B.R., S.A.-N., K.A.S.), School of Veterinary Medicine, University of California, Davis, California.
  • Rebhun RB; Department of Surgical and Radiological Sciences (J.L.W., R.B.R., S.A.-N., K.A.S.), School of Veterinary Medicine, University of California, Davis, California.
  • Burton JH; Clinical Sciences Department, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado (J.H.B.).
  • Al-Nadaf S; Department of Surgical and Radiological Sciences (J.L.W., R.B.R., S.A.-N., K.A.S.), School of Veterinary Medicine, University of California, Davis, California.
  • Skorupski KA; Department of Surgical and Radiological Sciences (J.L.W., R.B.R., S.A.-N., K.A.S.), School of Veterinary Medicine, University of California, Davis, California.
J Am Anim Hosp Assoc ; 59(4): 167-176, 2023 Jul 01.
Article em En | MEDLINE | ID: mdl-37432790
Canine mast cell tumors (MCTs) have highly variable clinical behavior, and predicting outcomes in individual dogs remains challenging. Many studies combine dogs with varying tumor grades, clinical stage, or treatments, confounding those results. The purpose of this retrospective study was to determine outcome and prognostic factors in a specific subset of dogs with high-grade, stage 2, cutaneous MCTs treated with adequate local control via surgery with or without radiation therapy and adjuvant cytotoxic chemotherapy. Seventeen dogs met the inclusion criteria, and the median survival time was 259 days. Development of local recurrence, tumor location, and presence of ulceration were all associated with shorter survival times. Tumor size, mitotic count, chemotherapy protocol, lymph node classification, and radiation therapy were not significantly associated with outcome. In this study, a specific population of dogs characterized by high-grade MCTs with local lymph node metastasis who received aggressive local and systemic therapy had a median survival of about 8.5 mo. Dogs with ulcerated tumors, recurrent tumors, or tumors located on the head had a worse outcome despite aggressive therapy. These results may serve as a basis of comparison for future research exploring alternative treatment combinations in this specific population of dogs.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças do Cão Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Revista: J Am Anim Hosp Assoc Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças do Cão Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Revista: J Am Anim Hosp Assoc Ano de publicação: 2023 Tipo de documento: Article